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ABSTRACT
Primary plasma cell leukemia (pPCL) is a rare and aggressive plasma cell 
neoplasm, with rapidly progressing clinical course. We evaluated the treatment status 
and survival outcomes of 69 Korean patients with pPCL. Of them, 59 patients were 
treated; 15 (25.4%) were treated initially with novel agent-based regimens with 
upfront autologous stem cell transplantation (ASCT), 7 (11.9%) with conventional 
chemotherapy with upfront ASCT, 21 (35.6%) with novel agent-based regimens only, 
and 16 (27.1%) were treated with conventional chemotherapy alone. Overall response 
rates after initial therapy were significantly higher in patients treated with novel agent-
based regimens compared with those treated with conventional chemotherapies (75% 
vs. 43.4%, P = 0.026). Median progression-free survival (PFS) and overall survival 
(OS) were 12.2 months and 16.1 months, respectively. The median PFS of the four 
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INTRODUCTION
Plasma cell leukemia (PCL) is a rare and highly 
aggressive plasma cell dyscrasia that occurs in 1–4% 
of patients with multiple myeloma (MM) [1, 2]. It is 
defined by the presence of more than 20% plasma cells 
in peripheral blood and an absolute plasma cell count 
≥ 2 × 109/L [3, 4]. PCL is classified as primary and 
secondary; ‘primary’ is used when PCL presents in 
patients without previous evidence of MM. Primary PCL 
(pPCL) represents ~ 60% of PCL, and has distinct clinical 
and laboratory features at presentation compared with 
those of MM. pPCL is generally diagnosed at a younger 
age than MM or secondary PCL. Patients with pPCL 
have more advanced International Staging System (ISS) 
stage of disease at presentation, frequently accompanied 
by hepatomegaly, splenomegaly, extramedullary 
disease, and extensive bone disease. Additionally, renal 
failure, hypercalcemia, thrombocytopenia, increased 
lactate dehydrogenase (LDH), and elevated plasma cell 
labeling index are more frequent in pPCL than MM 
[4, 5]. In studies investigating pPCL, it has been shown 
that pPCL has a different biological feature than MM in 
terms of immunophenotype expression, cytogenetics, 
gene-expression profiles, and microRNA signatures. 
Multiparametric flow cytometry revealed that PCL 
shows higher expression of CD20 antigens and lower 
CD9, CD56, CD117, and HLA-DR than MM [6, 7]. 
The frequencies of t(4;14), t(11;14), and t(14;16) were 
higher in pPCL, and del(17p13.1) was detected in about 
13–50% of pPCL cases [8–11]. In a study investigating 
gene expression profiles in 21 patients with pPCL, a 503-
gene signature, especially related to the NFκB pathway, 
structural organization of the cell, and cell adhesion/
migration differed from that in MM [12].
With these unfavorable clinical and biological 
characteristics at presentation, patients with pPCL have a 
dismal prognosis, with a median overall survival (OS) of 
only 7–12 months with conventional chemotherapy alone 
[1, 6, 13]. Although a few recent studies have suggested that 
the use of novel agents and performing autologous stem cell 
transplantation (ASCT) increased the survival outcomes in 
pPCL [14–16], the prognosis is still poor compared with 
MM, and the optimal therapy remains undefined. 
In this study, we collected data on Korean patients 
with pPCL. We then analyzed the clinical and cytogenetic 
characteristics, survival outcomes, and prognostic factors 
associated with OS.
RESULTS 
Patient population 
In total, 69 (0.6%) patients were diagnosed with 
pPCL among the 12,347 patients with MM from 18 
institutions between February 1998 and December 2015. 
Of them, 65 (94.2%) patients were diagnosed since 2005; 
the incidence was not different between the two time 
periods. Baseline clinical characteristics of all patients are 
summarized in Table 1. The median age of the patients 
was 63 years (range, 34–85 years); 46.4% were 65 years 
or older. The most common heavy-chain isotype was 
IgG (58.0%); 29.0% of patients had light chain disease. 
Thirty-three (47.8%) patients had low serum albumin 
levels (< 3.5 g/dL) and 48 (69.6%) patients had high ß2-
microglobulin levels (> 5.5 mg/L). Regarding the ISS, 
3 (4.3%) patients were stage I, 16 (23.2%) were stage 
II, and 48 (69.6%) were stage III. Thirty-nine (56.5%) 
patients showed leukocytosis (≥ 11 ×109/L), and 78.3% of 
patients had a platelet value of < 130 × 109/L at diagnosis. 
Organomegaly was detected in 23 (33.3%) patients and 
extramedullary disease was seen in 13 (18.8%) patients. 
Osteolytic bone lesions were present in 42 (60.9%) 
patients. Results of conventional cytogenetic studies and 
FISH were available in 46 and 42 patients, respectively. 
Results were mostly abnormal. The most common 
abnormalities on conventional cytogenetic studies were 
complex (63.0%) and hypodiploid (34.8%). Del(13q12), 
del(17p13), and t(11;14) were found in 13, 11, and 10 
patients, respectively (Table 2). 
Treatments 
Of the 69 patients, 59 were treated. The frontline 
treatments and responses are summarized in Table 3. 
Of the treated patients, 36 (61.0%) received a novel 
agent-based regimen as the first-line regimen, such as 
bortezomib, cyclophosphamide, and dexamethasone 
treatment groups–conventional chemotherapy alone, novel agents alone, conventional 
chemotherapy with ASCT, and novel agents with ASCT–were 1.2, 9.0, 10.5, and 26.4 
months, respectively (P < 0.001); the median OS of the four treatment groups were 
2.9, 12.3, 14.1, and 31.1 months, respectively (P < 0.001). The median OS was also 
significantly better in the patients with novel agents with ASCT versus other patients. 
In a multivariate analysis, an increased lactate dehydrogenase level, low albumin 
(< 3.5 g/dL), and non-CR after front-line treatment were independently associated with 
poor PFS and OS. In conclusion, the use of novel agent-based therapy with ASCT and 
achieving a deep response to front-line treatment are important in expecting improved 
PFS and OS in patients with pPCL.
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(VCD), or bortezomib, melphalan, and prednisolone 
(VMP), or bortezomib, doxorubicin, and dexamethasone 
(PAD), or cyclophosphamide, thalidomide, dexamethasone 
(CTD), or thalidomide and dexamethasone (TD), or 
bortezomib, thalidomide, and dexamethasone (VTD). 
Another 23 (39.0%) patients were treated with conventional 
chemotherapy as a first-line regimen such as, vincristine, 
doxorubicin, and dexamethasone (VAD), or melphalan and 
prednisolone, or cyclophosphamide and dexamethasone, 
or high dose dexamethasone, or cytarabine alone, 
or cyclophosphamide, doxorubicin, vincristine, and 
dexamethasone. Of the 23 patients who were treated with 
conventional chemotherapy as the first-line regimen, 12 
eventually received a novel agent-based regimen as a 
salvage therapy. Thus, 48 (69.6%) patients received novel-
agent-based regimes during the treatment period. 
Overall response rates (ORR) after initial therapy 
were significantly higher in patients treated with novel 
agent-based regimens compared with those treated with 
conventional chemotherapies (75% vs. 43.4%, P = 0.026). 
In patients who were treated with novel agent-based 
regimens, there was no difference of ORR between 
bortezomib- and thalidomide-based regimens. Upfront 
ASCT was performed in 22 (37.3%) patients. Twenty-
one patients maintained the best response at ASCT and 
one patient who had achieved VGPR after conventional 
chemotherapy eventually lost the response and progressed 
before ASCT. Twelve (54.5%) patients achieved complete 
remission (CR) after ASCT. One patient received 
consolidation therapy with bortezomib and dexamethasone 
after ASCT and 10 received maintenance therapy with 
thalidomide after ASCT. One (1.7%) patient received the 
Table 1: Baseline clinical characteristics of all patients (n = 69)
Variables 
Median age, year (range)
  ≥ 65, n. (%) 
   63.0 (34–85)
32 (46.4)   
Male, n. (%)  42 (60.9%)
ECOG PS ≥ 2 38 (55.1%)
Immunoglobulin (Ig) type, n. (%)
IgG
IgA
IgM
Light chain only 
40 (58.0)
8 (11.6)
1 (1.4)
20 (29.0)
International Staging System, n (%)
I
II
III
3 (4.3)
16 (23.2)
48 (69.6)
Serum hemoglobin, median (g/dL) 8.1 (4.1–13.1)
White blood cell count, median (×109/L) 13.0 (1.9–64.7)
Platelet count, median (×109/L) 90.0 (10–248)
Serum creatinine ≥ 2 mg/dL 29 (42.0%)
LDH > 1 × ULN 42 (60.9%)
Serum ß2-microglobulin, median (mg/L) 
> 5.5 mg/L, n (%)
8.9 (4.6–86.9)
48 (69.6%)
Serum albumin, median (g/dL) 3.5 (1.9–4.9)
Serum calcium, median (mg/dL) 9.4 (6.2–15.3)
Organomegaly 23 (33.3%)
Lytic bone lesions 42 (60.9%)
Extramedullary involvement 13 (18.8%)
Abbreviations: n, number; ECOG, Eastern Cooperative Oncology Group; PS, performance status; LDH, lactate 
dehydrogenase; ULN, upper limit of normal value. 
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allogeneic stem cell transplantation (SCT) after initial 
VMP induction chemotherapy, and progressed at 9.3 
months after allogeneic SCT.
Survival outcomes and factors associated OS 
Over a median follow-up of 16.5 months, the 
median PFS and OS were 12.2 months (95% CI 9.2–15.2, 
Figure 1A), and 16.1 months (95% CI 12.0–20.2, 
Figure 1B). In total, 5 (8.5%) patients died within less 
than 1 month and 20 (33.9%) died within less than 1 year 
following the diagnosis [early mortality(EM)]. The major 
causes of early mortality were disease progression and 
infection. The EM rate was significantly lower in patients 
who were initially treated with novel agents compared 
with those treated with conventional chemotherapies 
(22.2% vs. 52.5%, HR 0.262, 95% CI 0.084–0.814, 
P = 0.025). Patients who were initially treated with 
novel-agents had increased PFS and OS compared 
with those who were initially treated with conventional 
chemotherapy, but the difference was not statistically 
significant (PFS: 12.9 vs. 4.8 months, P = 0.059, OS: 
18.5 vs. 10.6 months, P = 0.168). The median PFS of the 
four treatment groups–conventional chemotherapy alone, 
novel agents alone, conventional chemotherapy with 
ASCT, and novel agents with ASCT–were 1.2, 9.0, 10.5, 
and 26.4 months, respectively (P < 0.001, Figure 2A). The 
median OS was also significantly better in patients who 
were treated with novel agents with ASCT (2.9 months 
in conventional chemotherapy alone vs. 12.3 months 
Figure 1: Kaplan-Meier survival curves for progression-free survival (PFS) (A) and overall survival (OS) (B) of treated patients (n = 59). 
Table 2: Cytogenetic abnormalities in the patients with primary plasma cell leukemia (n = 53)
Cytogenetic abnormalities Total number
(n = 53)
conventional cytogenetic studies 
(n = 46)
fluorescent in situ 
hybridization (n = 42)
Complex 29 29 -
Hypodiploid 16 16 -
del(13q14) 13 12 12
del(17p13) 11 5 9
t(11;14) 10 9 6
t(4;14) 9 1 8
t(14;16) 5 1 4
1q rearrangement 6 3 3
Not evaluable 16
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in novel agents alone vs. 14.1 months in conventional 
chemotherapy with ASCT vs. 31.1 months in novel agents 
with ASCT, P < 0.001, Figure 2B). In young patients 
(< 65 years), the median OS for patients undergoing ASCT 
was significantly longer than those who did not undergo 
ASCT (31.1 vs. 2.9 months, P < 0.001). Regarding the 
outcomes according to best response to front-line therapy, 
the median PFS and OS were significantly better in 
patients achieving a CR compared with those with very 
good partial responses, partial responses, or stable disease/
progressive disease (P < 0.001 for both, Figure 2C, 2D).
We evaluated the factors associated with PFS and 
OS in the 59 patients who were treated. The univariate 
analysis demonstrated that five clinical factors were 
associated with PFS and OS (P < 0.1); these factors 
were increased LDH level, thrombocytopenia, low serum 
albumin level, high serum β2-microglobulin and non-
CR after front-line treatment. Additionally, del17p was 
associated with OS in univariate analysis (Table 4). Cox 
multivariate analysis for PFS and OS was performed. 
Increased LDH level, low serum albumin, and non-CR 
after front-line treatment were associated significantly 
with PFS and OS (Table 5). The prognostic impact of 
each cytogenetic abnormality was evaluated in univariate 
analyses. Although patients with del17p showed a trend 
towards shorter OS compared to those without del17p 
(15.6 vs. 18.1 months, respectively, P = 0.086), none 
showed significant prognostic value. In a subgroup 
analysis (n = 47) excluding those patients who received 
conventional chemotherapy alone, patients with del17p 
had significantly shorter PFS and OS compared to those 
without del17p (Figure 3A, 3B). Additionally, patients 
with complex karyotypes showed a trend towards poor 
survival outcomes compared to those without complex 
karyotypes (Figure 3C, 3D). 
DISCUSSION 
Over the last two decades, the development of more 
effective agents and increased use of ASCT have resulted 
in improvements in survival outcome in patients with 
MM. However, this improvement did not clearly translate 
to patients with pPCL. The optimal induction therapy 
for pPCL patients is still unclear and survival outcome is 
insufficient compared with MM. A few retrospective studies 
have shown that treatment with novel agents induced higher 
response rates and prolonged survival than conventional 
chemotherapies. The Italian GIMEMA Multiple Myeloma 
Working Party reported a retrospective study of 29 patients 
with pPCL who were treated with frontline therapy with 
bortezomib. A bortezomib-based regimen was effective 
with an ORR of 79%, including ≥ VGPR (very good 
partial response) in 38% [17]. Additionally, a prospective 
study with lenalidomide and dexamethasone for pPCL 
resulted in an ORR of 73.9%, with at least 39% VGPR in 
23 patients with pPCL [18]. In the present study, induction 
Table 3: Summary of response according to front-line treatments (n = 59)
Patients undergoing upfront ASCT (n = 22)
Best response
after induction therapy
Best response 
after ASCT
Front-line regimen, n (%) CR VGPR ≥ PR CR VGPR ≥ PR
Novel agent-based
15
 (68.2%)
4
(26.7%)
4
(26.7%)
12
(80.0%)
7
(46.7%)
3
(20.0%)
13
(86.7%)
   Bortezomib-based 4 1 2 4 2 1 4
   Thalidomide-based 11 3 2 8 5 2 9
   Bortezomib+thalidomide 0 0 0 0 0 0 0
Conventional chemotherapy 7
(31.8%)
2
(28.6%)
2
(28.6%)
6
(85.7%)
5
(71.4%)
0 5
(71.4%)
Patients receiving chemotherapy alone (n = 37)
Novel agent-based
21
(56.7%)
4
(19.0%)
3
(14.3%)
15
(71.4%)
   Bortezomib-based 15 2 3 10
   Thalidomide-based 3 1 0 2
   Bortezomib+thalidomide 3 1 0 3
Conventional chemotherapy 16
(43.2%)
0 0 4
(25.0%)
Abbreviations: n, number; ASCT, autologous stem cell transplantation; CR, complete response; VGPR, very good partial 
response; PR, partial response. 
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therapy with novel agents decreased the EM rate and 
increased the response rates compared with conventional 
therapy. Bortezomib- or thalidomide-based regimens 
achieved ORRs of ~70%, and combination treatment with 
bortezomib and thalidomide achieved more than PR in 
all patients. In a report of two cases with secondary PCL, 
combined therapy with bortezomib, lenalidomide, and 
dexamethasone resulted in CR [19]. Thus, a combination 
of novel agents such as bortezomib and thalidomide, or 
bortezomib and lenalidomide, seems to be very promising 
as a front-line therapy for pPCL.
Although frontline therapy with novel agents 
decreased the EM rates and increased the response rate 
in our study, it did not significantly improve the survival 
in patients with pPCL. The most improved survival 
was achieved in patients who received treatment with 
novel agents incorporated with ASCT. There are limited 
data on the role of transplantation in pPCL. The largest 
reported study is a retrospective analysis of 272 patients 
who underwent ASCT by the European Group for Blood 
and Marrow Transplantation [20]. A higher proportion of 
patients with pPCL than MM patients were in CR at day 
100 post-transplantation (41.2% vs. 28.2%, P < 0.001), 
but median PFS and OS were significantly shorter 
compared with MM (PFS: 14.3 vs. 27.4 months, OS: 25.7 
vs. 62.2 months). In a study of 97 patients with pPCL 
who underwent ASCT by the Center for International 
Blood and Marrow Transplant Research, PFS and OS 
at 3 years were 34% and 61%, respectively [21]. These 
studies support that ASCT resulted in deep responses and 
played a role in relatively prolonged remission. However, 
early relapse after transplantation is a major hurdle to 
overcome to improve survival in pPCL. Recently, results 
of a prospective study to evaluate the efficacy of an 
alternative regimen that combined induction therapy with 
bortezomib and ASCT followed by allogeneic SCT or 
bortezomib/lenalidomide maintenance was reported [11]. 
There 40 patients with pPCL received alternative induction 
therapy with PAD/VCD; the ORR was 69%, including 
10% CR and 26% VGPR. After transplantation, 92% of 
Figure 2: Kaplan-Meier survival curves for PFS and OS according to treatment groups (A, B) and best response to front-line treatment (C, D). 
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patients achieved more than PR. The median PFS and OS 
were 15.1 and 36.3 months, respectively. While 35% of 
patients experienced relapse after allogeneic SCT, only 1 
of 7 patients who received maintenance therapy relapsed. 
Although small in number, lenalidomide maintenance 
therapy after transplantation could be beneficial in reducing 
early relapse and improving the duration of remission in 
pPCL. Thus, rapid reduction of tumor burden with novel 
agents and ASCT followed by maintenance therapy may 
be a successful treatment strategy in patients with pPCL.
In the present study, elevated serum LDH and low 
serum albumin level were significantly associated with 
poor OS in pPCL. Additionally, patients who did not 
achieve a complete response after front-line treatment had 
a very poor prognosis. These risk factors are known to be 
associated with prognosis in newly diagnosed MM [22]. 
Beyond these risk factors, cytogenetic abnormalities 
are important predictors for MM, and a few studies 
have investigated the prognostic role of cytogenetic 
abnormalities in pPCL. Because most pPCL studies 
were based on a small number of patients and were 
retrospective in nature, the results regarding the prognostic 
impact of cytogenetic abnormalities differed in each study. 
In some retrospective studies, del(13q), del(17p), del(1p), 
ampl(1q), and a complex karyotype were associated with 
reduced OS, and t(11;14) was associated with favorable 
outcomes [9, 23]. A recent prospective study, found no 
prognostic value of abnormalities on FISH or conventional 
cytogenetic analyses [11]. In this study, cytogenetic 
abnormalities also showed no prognostic value. However, 
with the exception of patients who received conventional 
chemotherapy with much shorter survival outcomes 
compared with other patient groups, del17p and complex 
karyotype showed trends towards associated with poor 
PFS and OS. Thus, larger prospective studies with uniform 
treatment are needed to further examine the prognostic 
role of cytogenetic abnormalities in pPCL. Additionally, 
gene-expression profiling and whole-genome sequencing 
Figure 3: Kaplan-Meier survival curves for PFS and OS according to del(17p13) (A, B) and complex karyotype (C, D) in patients 
(n = 47) except those who received conventional chemotherapy alone. 
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may be helpful in analyzing and identifying a new 
prognosis model in pPCL.
In conclusion, induction therapy with novel agents 
decreased the EM rate and increased the response rates in 
patients with pPCL. Additionally, performance of ASCT 
resulted in deep responses and had a role in relatively 
prolonged remission in pPCL patients who were eligible 
for ASCT. However, remission duration of pPCL was 
Table 4: Univariate analysis of risk factors for progression-free survival and overall survival (n = 59)
Variables PFS OS
HR (95% CI) P-value HR (95% CI) P-value
Age > 65 years 1.51 (0.80–2.84) 0.196 1.64 (0.83–3.21) 0.147
Gender 0.61 (0.33–1.14) 0.127 0.69 (0.36–1.34) 0.282
PS ECOG ≥ 2 1.47 (0.80–2.70) 0.204 1.69 (0.89–3.21) 0.109
Organomegaly 1.39 (0.73–2.66) 0.310 1.28 (0.64–2.52) 0.477
Extramedullary disease 0.76 (0.36–1.61) 0.483 1.06 (0.50–2.26) 0.870
Leukocytosis (≥ 11 × 109/L) 1.28 (0.68–2.39) 0.432 1.16 (0.61–2.22) 0.644
LDH > (1 × ULN) 4.74 (2.16–10.41) < 0.001 6.32 (2.44–16.35) < 0.001
Platelets < 130 × 109/L 2.17 (0.90–5.22) 0.083 2.18 (0.90–5.28) 0.084
Hemoglobin < 8.0 g/dL 0.62 (0.33–1.17) 0.143 0.63 (0.32–1.22) 0.178
Serum creatinine ≥ 2 mg/dL 1.36 (0.71–2.62) 0.345 1.43 (0.73–2.78) 0.286
Serum calcium > 11.0 mg/dl 1.65 (0.85–3.20) 0.137 1.63 (0.82–3.22) 0.160
Serum albumin < 3.5 g/dL 2.02 (1.09–3.74) 0.025 1.96 (1.02–3.75) 0.042
Serum β2-microglobulin > 5.5 mg/L 2.16 (1.01–4.60) 0.045 2.12 (0.98–4.55) 0.054
BM plasma cells > 60% 1.36 (0.72–2.57) 0.337 0.55 (0.27–1.12) 0.100
Complex karyotype 1.64 (0.72–3.70) 0.233 1.82 (0.77–4.28) 0.168
del(17p13) 1.84 (0.84–4.03) 0.125 2.03 (0.90–4.55) 0.086
Non-CR after front-line treatment 4.68 (2.03–10.76) < 0.001 5.10 (2.06–12.63) < 0.001
Abbreviations: ECOG, Eastern Cooperative Oncology Group; PS, performance status; LDH, lactate dehydrogenase; ULN, 
upper limit of normal value; BM, bone marrow; CR, complete response; ASCT, autologous stem cell transplant.
Table 5: Multivariate analysis of risk factors for progression-free survival and overall survival (n = 59)
Progression-free survival
Hazard ratio (95% CI) P-value
LDH > (1 × ULN) 6.21 (2.04–16.02) < 0.001
Non-CR after front-line treatment 4.23 (1.55–11.51) 0.005
Serum albumin < 3.5 g/dL 2.69 (1.40–5.17) 0.003
Platelets < 130 × 109/L 0.93 (0.35–2.48) 0.893
Serum β2-microglobulin > 5.5 mg/L 1.81 (0.77–4.24) 0.173
Overall survival
Hazard ratio (95% CI) P-Value
LDH > (1 × ULN) 8.03 (2.11–30.48) 0.002
Non-CR after front-line treatment 8.31 (2.20–31.33) 0.002
Serum albumin < 3.5 g/dL 3.25 (1.42–7.42) 0.005
Serum β2-microglobulin > 5.5 mg/L 2.59 (0.97–6.91) 0.058
Platelets < 130 × 109/L 1.42 (0.37–5.35) 0.604
del(17p13) 0.88 (0.35–2.18) 0.788
Abbreviations: LDH, lactate dehydrogenase; ULN, upper limit of normal value; CR, complete response; ASCT, autologous 
stem cell transplant.
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still shorter than in MM. Consolidation/maintenance 
treatment with novel agents may be helpful in improving 
the survival. Additionally, larger prospective studies are 
needed to establish the optimal treatment strategy and to 
identify prognostic factors in pPCL.  
MATERIALS AND METHODS 
We collected the data retrospectively on patients 
with pPCL diagnosed at the participating centers of 
the Korea Multiple Myeloma Working Party between 
February 1998 and December 2015. The diagnostic criteria 
for PCL are the presence of > 2 × 109/L peripheral blood 
plasma cells or plasmacytosis accounting of > 20% in a 
differential white blood cell count [4]. In this study, we 
excluded secondary PCL that developed from relapsed or 
refractory MM. To investigate the clinical characteristics 
at diagnosis, data for patients with pPCL who were 
treated or not treated were collected. Treatment regimens, 
response rates, and survival outcomes were analyzed in 
patients who were treated. Clinical staging was performed 
using the ISS. Cytogenetic abnormalities were assessed 
by conventional cytogenetic studies or fluorescent in situ 
hybridization (FISH). Treatment response was assessed 
according to the International Myeloma Working Group 
criteria [4]. ORR was defined as PR or better. This study 
was approved by the Institutional Review Board of each 
participating hospital in accordance with the Declaration 
of Helsinki. 
Statistical analysis
Discrete and continuous variables were evaluated 
using Fisher’s exact test and the Mann–Whitney U–test, 
respectively. Progression-free survival (PFS) was 
calculated from the start of treatment to disease 
progression, or deaths resulting from any causes other 
than disease progression censored. OS was defined as 
the period from the date of diagnosis to the date of the 
last follow-up or death from any cause. PFS and OS were 
evaluated using Kaplan-Meier estimates and compared 
using the log-rank test. The estimate of the relative risk of 
event and its 95% confidence interval (CI) were estimated 
using the Cox proportional hazard model. Covariates 
having a P-value < 0.1 in the univariate analyses were 
included in a Cox proportional hazards regression model. 
All statistical computations were performed using SPSS 
software (ver. 21; SPSS Inc., Chicago, IL, USA). A 
P-value < 0.05 was considered to indicate statistical 
significance in all analyses.
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